RA B-Cell Depletion

Clifton Bingham, M.D. - Jon Giles, M.D.

Abstract 6 (Poster): Safety and Clinical Activity of Ocrelizumab (a Humanized Antibody Targeting CD20+ B Cells) in Combination with Methotrexate in Moderate-Severe Rheumatoid Arthritis Patients (Ph I/I I ACTION Study)

Abstract 463 (Poster): TRU-015, a Small Modular ImmunoPharmaceutical (SMIPTM) Drug Candidate Directed Against CD20, Demonstrates Clinical Improvement in Subjects with Rheumatoid Arthritis

Abstract 725: Long-Term Efficacy and Safety of a Repeat Treatment Course of Rituximab in Rheumatoid Arthritis Patients with an Inadequate Response to One or More TNF Inhibitors

Abstract 726: TNF Inhibitors in Rheumatoid Arthritis Patients Previously Treated with Rituximab

Abstract 1234: Vaccination Against Influenza in Rheumatoid Arthritis Patients: The effect of Rituximab on the Humoral Response

Abstract 2122: HuMax-CD20, a Novel Fully Human Monoclonal IgG1 Antibody in the Treatment of Rheumatoid Arthritis

footer line

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.